Quan Wu

Quan Wu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QWQuan Wu
Quan Wu
ZCZhongyi Cheng
Zhongyi Cheng
JZJun Zhu
Jun Zhu
WXWeiqing Xu
Weiqing Xu
XPXiaojun Peng
Xiaojun Peng
PFPingsheng Fan
Pingsheng Fan
Suberoylanilide hydroxamic acid (SAHA) is a well-known histone deacetylase (HDAC) inhibitor and has been used as practical therapy for breast cancer and non-small cell lung cancer (NSCLC). It is previously demonstrated that SAHA treatment could extensively change the profile of acetylome and proteome in cancer cells. However, little is known about the impact of SAHA on other protein modifications and the crosstalks among different modifications and proteome, hindering the deep understanding of SAHA-mediated cancer therapy. In this work, by using SILAC technique, antibody-based affinity enrichment and high-resolution LC-MS/MS analysis, we investigated quantitative proteome, acetylome and ubiquitylome as well as crosstalks among the three datasets in A549 cells toward SAHA treatment. In total, 2968 proteins, 1099 acetylation sites and 1012 ubiquitination sites were quantified in response to SAHA treatment, respectively. With the aid of intensive bioinformatics, we revealed that the proteome and ubiquitylome were negatively related upon SAHA treatment. Moreover, the impact of SAHA on acetylome resulted in 258 up-regulated and 99 down-regulated acetylation sites at the threshold of 1.5 folds. Finally, we identified 55 common sites with both acetylation and ubiquitination, among which ubiquitination level in 43 sites (78.2%) was positive related to acetylation level.

28 June 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XCXueran Chen
Xueran Chen
SZShangrong Zhang
Shangrong Zhang
ZWZhen Wang
Zhen Wang
FWFengsong Wang
Fengsong Wang
XCXinwang Cao
Xinwang Cao
ZFZhiyou Fang
Zhiyou Fang
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world and metastasis is the leading cause of death associated with HCC. Hypoxia triggers the epithelial-mesenchymal transition (EMT) of cancer cells, which enhances their malignant character and elevates metastatic risk. Supervillin associates tightly with the membrane and cytoskeleton, promoting cell motility, invasiveness, and cell survival. However, the roles of supervillin in HCC metastasis remain unclear. Methods: Tissue microarray technology was used to immunohistochemically stain for supervillin antibody in 173 HCC tissue specimens and expression levels correlated with the clinicopathological variables. Tumor cell motility and invasiveness, as well as changes in the mRNA expression levels of genes associated with cancer cell EMT, were investigated. The relationship between supervillin and Rho GTPases was examined using Co-IP and GST pull-down. Results: Hypoxia-induced upregulation of supervillin promoted cancer cell migration and invasion via the activation of the ERK/p38 pathway downstream of RhoA/ROCK signaling. Furthermore, supervillin regulated the expression of EMT genes during hypoxia and accelerated the metastasis of HCC in vivo. Conclusions: Hypoxia-induced increase in supervillin expression is a significant and independent predictor of cancer metastasis, which leads to poor survival in HCC patients. Our results suggest that supervillin may be a candidate prognostic factor for HCC and a valuable target for therapy.

20 August 2013 in Journal of Proteome Research
Verified
Journal Article
Closed access
QWQuan Wu
Quan Wu
WXWeiqing Xu
Weiqing Xu
LCLejie Cao
Lejie Cao
XLXin Li
Xin Li
THTieming He
Tieming He
WLWenting Li
Wenting Li

29 January 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XZXiaoyu Zhu
Xiaoyu Zhu
XLXin Liu
Xin Liu
ZCZhongyi Cheng
Zhongyi Cheng
JZJun Zhu
Jun Zhu
LXLei Xu
Lei Xu
QWQuan Wu
Quan Wu
Valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) are both HDAC inhibitors (HDACi). Previous studies indicated that both inhibitors show therapeutic effects on acute myeloid leukaemia (AML), while the differential impacts of the two different HDACi on AML treatment still remains elusive. In this study, using 3-plex SILAC based quantitative proteomics technique, anti-acetyllysine antibody based affinity enrichment, high resolution LC-MS/MS and intensive bioinformatic analysis, the quantitative proteome and acetylome in SAHA and VPA treated AML HL60 cells were extensively studied. In total, 5,775 proteins and 1,124 lysine acetylation sites were successfully obtained in response to VAP and SAHA treatment. It is found that VPA and SAHA treatment differently induced proteome and acetylome profiling in AML HL60 cells. This study revealed the differential impacts of VPA and SAHA on proteome/acetylome in AML cells, deepening our understanding of HDAC inhibitor mediated AML therapeutics.

3 March 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
XFXiao Feng
Xiao Feng
FBFan Bu
Fan Bu
LHLiguo Huang
Liguo Huang
WXWeilong Xu
Weilong Xu
WWWenbin Wang
Wenbin Wang
QWQuan Wu
Quan Wu

11 February 2021 in Proteomics
Verified
Journal Article
Closed access
PDF file
SKShuai Kong
Shuai Kong
LDLu Ding
Lu Ding
CFChenkun Fan
Chenkun Fan
YLYun Li
Yun Li
CWChi Wang
Chi Wang
FWFengsong Wang
Fengsong Wang